ArticleJournal of virology2003
Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 100 citations in OpenAlex.
- Whole-genome sequencing of adenovirus 41 directly from wastewater using nested overlapping PCR and MinION.Microbiology spectrum · 2026Article
- Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin.Molecular therapy. Oncology · 2025Article
- Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies.International journal of molecular sciences · 2024Article
- Concepts in Oncolytic Adenovirus Therapy.International journal of molecular sciences · 2021Review
- Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.Cancer science · 2021Article
- Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.Cancers · 2021Review
- The infectivity of progeny adenovirus in the presence of neutralizing antibody.The Journal of general virology · 2021Article
- Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration.Scientific reports · 2018Article
- Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.Nature communications · 2018Article
- Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.Viruses · 2014Review
- Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa.PloS one · 2013Article
- Article
- HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.Cancer gene therapy · 2012Article
- Peptide targeting of adenoviral vectors to augment tumor gene transfer.Cancer gene therapy · 2012Article
- A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.Journal of virology · 2012Article
- Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes.ISRN endocrinology · 2012Article
- Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses.Pharmaceutics · 2011Article
- Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.Molecular cancer · 2010Article
- Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.Gene therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary receptor, the coxsackievirus and adenovirus receptor (CAR), and the secondary receptor, alphav integrins, are the tropism determinants of adenovirus (Ad) type 5. Inhibition of the interaction of both the fiber with CAR and the penton base with the alphav integrin appears to be crucial to the development of targeted Ad vectors, which specifically transduce a given cell population. In this study, we developed Ad vectors with ablation of both CAR and alphav integrin binding by mutating the fiber knob and the RGD motif of the penton base. We also replaced the fiber shaft domain with that derived from Ad type 35. High transduction efficiency in the mouse liver was suppressed approximately 130- to 270-fold by intravenous administration of the double-mutant Ad vectors, which mutated two domains each of the fiber knob and shaft and the RGD motif of the penton base compared with those of conventional Ad vectors (type 5). Most significantly, the triple-mutant Ad vector containing the fiber knob with ablation of CAR binding ability, the fiber shaft of Ad type 35, and the penton base with a deletion of the RGD motif mediated a >30,000-fold lower level of mouse liver transduction than the conventional Ad vectors. This triple-mutant Ad vector also mediated reduced transduction in other organs (the spleen, kidney, heart, and lung). Viral DNA analysis showed that systemically delivered triple-mutant Ad vector was primarily taken up by liver nonparenchymal cells and that most viral DNAs were easily degraded, resulting in little gene expression in the liver. These results suggest that the fiber knob, fiber shaft, and RGD motif of the penton base each plays an important role in Ad vector-mediated transduction to the mouse liver and that the triple-mutant Ad vector exhibits little tropism to any organs and appears to be a fundamental vector for targeted Ad vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.